Update on the Prenatal Diagnosis and Treatment of Congenital Adrenal Hyperplasia due to 11β-Hydroxylase Deficiency
Lists
Only you see this
Abstract
11beta-Hydroxylase deficiency is a common form of congenital adrenal hyperplasia causing virilization of the female fetus and hypertension. DNA analysis of the gene (CYP11B1) encoding 11beta-hydroxylase has been reported previously to be effective in the prenatal diagnosis of one affected female fetus. In that case, prenatal treatment with dexamethasone resulted in normal female genitalia. We now report five new pregnancies that underwent prenatal diagnosis for 11beta-hydroxylase deficiency. In the first family, the proband is homozygous for a T318M mutation and all fetuses from four subsequent pregnancies are carriers. In a second family, the mother is homozygous for a A331V mutation and was started on dexamethasone, but identification of a homozygous normal fetus led to the discontinuation of treatment. In another family, the fetus was a male homozygous for R384Q and treatment was discontinued. Lastly, a novel G444D mutation in exon 8 was identified and proven to reduce 11beta-hydroxylase activity.
BibTeX
@article{motaghedi2005update,
author = {Roja Motaghedi and Brian P. Betensky and Bozena Slowinska and Barbara Cerame and María Cabrer and Maria I. New and Robert C. Wilson},
title = {{Update on the Prenatal Diagnosis and Treatment of Congenital Adrenal Hyperplasia due to 11β-Hydroxylase Deficiency}},
journal = {Journal of Pediatric Endocrinology and Metabolism},
year = {2005},
doi = {10.1515/jpem.2005.18.2.133},
}Loading related content...